Chronic heart failure: Role of the GP in management

被引：1
作者：
Piterman, Leon [1 ,2 ]
Yang, Hui [1 ,2 ,3 ]
Yin, Zhaoxia [4 ]
机构：
[1] Monash Univ, Dept Gen Practice, Melbourne, Vic, Australia
[2] Monash Inst Hlth & Clin Educ, China GP Program, Melbourne, Vic, Australia
[3] Shenzhen Int Primary Hlth Care Res Inst, Shenzhen, Guangdong, Peoples R China
[4] Shenzhen Univ, Luohu Hosp Grp, Affiliated Hosp 3, Shenzhen, Guangdong, Peoples R China
来源：
FAMILY MEDICINE AND COMMUNITY HEALTH | 2018年 / 6卷 / 01期
关键词：
Chronic heart failure; general practice; team based care;
D O I：
10.15212/FMCH.2018.0100
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
The commonest cause of chronic heat failure in China is ischemic heart disease, followed by hypertension and valvular heart disease. Echocardiography is essential in establishing a diagnosis as well as helping to identify a cause and to monitor progress. Management includes nonpharmacological as well as pharmacological treatment, and self-care with careful monitoring of salt and fluid intake as well as regular weight measurement. Care planning and team-based care are essential in managing patients with chronic heart failure, who often have concurrent multimorbidity and are receiving polypharmacy.
引用
收藏
页码：3 / 9
页数：7
相关论文
共 50 条
  • [31] Australia's health care reform agenda: Implications for the nurses' role in chronic heart failure management
    Betihavas, Vasiliki
    Newton, Phillip J.
    Du, Hui Yun
    Macdonald, Peter S.
    Frost, Steven A.
    Stewart, Simon
    Davidson, Patricia M.
    AUSTRALIAN CRITICAL CARE, 2011, 24 (03) : 189 - 197
  • [32] Heart rate variability in chronic heart failure and its role in prognosis of the disease
    Arbolishvili, G. N.
    Mareev, V. Yu.
    Orlova, Ya. A.
    Belenkov, Yu. N.
    KARDIOLOGIYA, 2006, 46 (12) : 4 - 11
  • [33] Role of ivabradine and heart rate lowering in chronic heart failure: guideline update
    Chow, Sheryl L.
    Page, Robert L., II
    Depre, Christophe
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2018, 16 (07) : 515 - 526
  • [34] New and emerging pharmacologic strategies in the management of chronic heart failure
    Krum, H
    CLINICAL CARDIOLOGY, 2000, 23 (10) : 724 - 730
  • [35] The German National Disease Management Guideline "Chronic Heart Failure"
    Weinbrenner, S.
    Langer, T.
    Scherer, M.
    Stoerk, S.
    Ertl, G.
    Muth, Ch.
    Hoppe, U. C.
    Kopp, I.
    Ollenschlaeger, G.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2012, 137 (05) : 219 - 226
  • [36] Medical therapies for the management of cardiomyopathy and chronic congestive heart failure
    Meyers D.
    Current Cardiovascular Risk Reports, 2009, 3 (5) : 315 - 322
  • [37] The role of sarcopenia questionnaires in hospitalized patients with chronic heart failure
    Wenxue Zhao
    Miao Lu
    Xiangming Wang
    Yan Guo
    Aging Clinical and Experimental Research, 2021, 33 : 339 - 344
  • [38] Role of endotoxin and systemic inflammation in chronic heart failure pathogenesis
    Egorova, E. N.
    Mazur, V. V.
    Kalinkin, M. N.
    Mazur, E. S.
    RUSSIAN JOURNAL OF CARDIOLOGY, 2012, (03): : 25 - 27
  • [39] The predictive role of circulating microparticles in patients with chronic heart failure
    Berezin, Alexander E.
    Kremzer, Alexander A.
    Martovitskaya, Yulia V.
    Samura, Tatyana A.
    Berezina, Tatyana A.
    BBA CLINICAL, 2015, 3 : 18 - 24
  • [40] The role of sarcopenia questionnaires in hospitalized patients with chronic heart failure
    Zhao, Wenxue
    Lu, Miao
    Wang, Xiangming
    Guo, Yan
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2021, 33 (02) : 339 - 344
12345